Mechanism of acute coronary syndrome and local delivery therapy

急性冠脉综合征的发病机制及局部给药治疗

• 批准号: 08670764
• 负责人: TOMARU Takanobu
• 金额: $ 1.41万
• 依托单位: University of Tokyo
• 依托单位国家: 日本
• 项目类别: Grant-in-Aid for Scientific Research (C)
• 财政年份: 1996
• 资助国家: 日本
• 起止时间: 1996 至 1997
• 项目状态: 已结题
• 来源: https://kaken.nii.ac.jp/grant/KAKENHI-PROJECT-08670764/
• 关键词: Acute Coronary Syndrome; CD63; Local Delivery; 血管内局所投与; 抗トロンビン剤; 血管内視鉄

This study was designed to clarify the pathogenesis of acute coronary syndrome(ACS) and to evaluate the efficacy of local treatment of thrombosis with various antithrombotic drugs using our novel porous balloon catheter. In patients with ACS, CD63 antigen and chemise was expressed at vascular smooth muscle cell (VSMC) of fresh atherosclerotic plaque. On the other hand, these molecules were not detected in the plaque of stable angina. Experimental study demonstrated that local delivery of antithrombin using a novel porous balloon catheter could prevent thrombus formation in injured atherosclerotic arteries without significant influence on systemic coagulability. In patients with ACS, local delivery of antithrombin or t-PA could prevent thrombus formation after PTCA and could induce thrombolysis.

本研究旨在阐明急性冠状动脉综合征（ACS）的发病机制，并评价使用我们的新型多孔球囊导管使用各种抗栓药物局部治疗血栓形成的疗效。在ACS患者中，CD63抗原和chemise在新鲜动脉粥样硬化斑块的血管平滑肌细胞（VSMC）表达。另一方面，在稳定型心绞痛的斑块中没有检测到这些分子。实验研究表明，使用一种新型多孔球囊导管局部输送抗凝血酶可以防止受损动脉粥样硬化动脉血栓形成，而对全身凝血能力没有明显影响。ACS患者局部给予抗凝血酶或t-PA可预防PTCA后血栓形成，并可诱导溶栓。

项目成果

Tomaru T, Yoshimura A, Aoki N, Omata M, Geschwind HJ, Uchida Y.: "Local Delivery of Antithrombotic drug Inhibits Neointimal hyperplasia Following Arterial Injury"J Interven Cardiol. 10. 51-60 (1997)

Tomaru T、Yoshimura A、Aoki N、Omata M、Geschwind HJ、Uchida Y.：“抗血栓药物局部给药可抑制动脉损伤后的新内膜增生”J Interven Cardiol。